MAP kinases in inflammatory bowel disease

Clinica Chimica Acta

Volumn 412, Issue 7-8, 2011, Pages 513-520

  Coskun, Mehmet ^a,b   Olsen, Jørgen ^b   Seidelin, Jakob Benedict ^a   Nielsen, Ole Haagen ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Inflammation; Inflammatory bowel disease; MAP kinase; Therapy; Transcription factors

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; DELMITIDE; DORAMAPIMOD; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; ML 3403; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NATALIZUMAB; PLACEBO; SEMAPIMOD; STAT PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR CDX2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ARTHRALGIA; BACKACHE; CELL ACTIVITY; CLINICAL TRIAL (TOPIC); CROHN DISEASE; CYTOKINE PRODUCTION; DIZZINESS; DRUG DOSE COMPARISON; DRUG TARGETING; DRUG TREATMENT FAILURE; ENTERITIS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEADACHE; HUMAN; LIVER FUNCTION TEST; MULTIPLE CYCLE TREATMENT; NONHUMAN; PATHOGENESIS; PHLEBITIS; PRIORITY JOURNAL; PROTEIN TARGETING; RASH; REGULATORY MECHANISM; REMISSION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION;

CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; INFLAMMATORY BOWEL DISEASES; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS;

MAMMALIA;

EID: 79551477677     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.12.020     Document Type: Review

References (155)

1. Nielsen O.H., Seidelin J., Munck L.K., Rogler G. Use of biological molecules in the treatment of inflammatory bowel disease. J Int Med 2011, 269.
2. Cuadrado A., Nebreda A.R. Mechanisms and functions of p38 MAPK signalling. Biochem J 2010, 429:403-417.
3. Rincon M., Davis R.J. Regulation of the immune response by stress-activated protein kinases. Immunol Rev 2009, 228:212-224.
4. Weston C.R., Davis R.J. The JNK signal transduction pathway. Curr Opin Cell Biol 2007, 19:142-149.
5. Kyriakis J.M., Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001, 81:807-869.
6. Yoon S., Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 2006, 24:21-44.
7. Schieven G.L. The p38alpha kinase plays a central role in inflammation. Curr Top Med Chem 2009, 9:1038-1048.
8. Roy P.K., Rashid F., Bragg J., Ibdah J.A. Role of the JNK signal transduction pathway in inflammatory bowel disease. World J Gastroenterol 2008, 14:200-202.
9. Chen Z., Gibson T.B., Robinson F., et al. MAP kinases. Chem Rev 2001, 101:2449-2476.
10. Kim E.K., Choi E.J. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 2010, 1802:396-405.
11. Johnson G.L., Nakamura K. The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. Biochim Biophys Acta 2007, 1773:1341-1348.
12. Cuenda A., Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 2007, 1773:1358-1375.
13. Mitsuyama K., Suzuki A., Tomiyasu N., et al. Pro-inflammatory signaling by Jun-N-terminal kinase in inflammatory bowel disease. Int J Mol Med 2006, 17:449-455.
14. Waetzig G.H., Seegert D., Rosenstiel P., Nikolaus S., Schreiber S. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol 2002, 168:5342-5351.
15. Broom O.J., Widjaya B., Troelsen J., Olsen J., Nielsen O.H. Mitogen activated protein kinases: a role in inflammatory bowel disease?. Clin Exp Immunol 2009, 158:272-280.
16. Chang L., Karin M. Mammalian MAP kinase signalling cascades. Nature 2001, 410:37-40.
17. Pearson G., Robinson F., Beers G.T., et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001, 22:153-183.
18. Cobb M.H., Goldsmith E.J. How MAP kinases are regulated. J Biol Chem 1995, 270:14843-14846.
19. Canagarajah B.J., Khokhlatchev A., Cobb M.H., Goldsmith E.J. Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell 1997, 90:859-869.
20. Enslen H., Raingeaud J., Davis R.J. Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6. J Biol Chem 1998, 273:1741-1748.
21. Alonso G., Ambrosino C., Jones M., Nebreda A.R. Differential activation of p38 mitogen-activated protein kinase isoforms depending on signal strength. J Biol Chem 2000, 275:40641-40648.
22. Jiang Y., Gram H., Zhao M., et al. Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38delta. J Biol Chem 1997, 272:30122-30128.
23. Brancho D., Tanaka N., Jaeschke A., et al. Mechanism of p38 MAP kinase activation in vivo. Genes Dev 2003, 17:1969-1978.
24. Craig E.A., Stevens M.V., Vaillancourt R.R., Camenisch T.D. MAP3Ks as central regulators of cell fate during development. Dev Dyn 2008, 237:3102-3114.
25. Tournier C., Dong C., Turner T.K., Jones S.N., Flavell R.A., Davis R.J. MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. Genes Dev 2001, 15:1419-1426.
26. Davis R.J. Signal transduction by the JNK group of MAP kinases. Cell 2000, 103:239-252.
27. Roux P.P., Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004, 68:320-344.
28. Carter A.B., Knudtson K.L., Monick M.M., Hunninghake G.W. The p38 mitogen-activated protein kinase is required for NF-kappaB-dependent gene expression. The role of TATA-binding protein (TBP). J Biol Chem 1999, 274:30858-30863.
29. Vermeulen L., De W.G., Van D.P., Vanden Berghe W., Haegeman G. Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J 2003, 22:1313-1324.
30. Ghosh S., May M.J., Kopp E.B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998, 16:225-260.
31. Hoffmann A., Baltimore D. Circuitry of nuclear factor kappaB signaling. Immunol Rev 2006, 210:171-186.
32. Rogler G., Brand K., Vogl D., et al. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998, 115:357-369.
33. Schreiber S., Nikolaus S., Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut 1998, 42:477-484.
34. Ellis R.D., Goodlad J.R., Limb G.A., Powell J.J., Thompson R.P., Punchard N.A. Activation of nuclear factor kappa B in Crohn's disease. Inflamm Res 1998, 47:440-445.
35. Neurath M.F., Fuss I., Schurmann G., et al. Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease. Ann NY Acad Sci 1998, 859:149-159.
36. Kristensen N.N., Olsen J., Gad M., Claesson M.H. Genome-wide expression profiling during protection from colitis by regulatory T cells. Inflamm Bowel Dis 2008, 14:75-87.
37. Neurath M.F., Pettersson S., Meyer Zum Buschenfelde K.H., Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 1996, 2:998-1004.
38. Vallabhapurapu S., Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009, 27:693-733.
39. Pasparakis M. Regulation of tissue homeostasis by NF-kappaB signalling: implications for inflammatory diseases. Nat Rev Immunol 2009, 9:778-788.
40. Ulivi V., Giannoni P., Gentili C., Cancedda R., Descalzi F. p38/NF-kB-dependent expression of COX-2 during differentiation and inflammatory response of chondrocytes. J Cell Biochem 2008, 104:1393-1406.
41. Rayet B., Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999, 18:6938-6947.
42. Braun T., Carvalho G., Fabre C., Grosjean J., Fenaux P., Kroemer G. Targeting NF-kappaB in hematologic malignancies. Cell Death Differ 2006, 13:748-758.
43. Ghosh S., Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002, 109(Suppl):S81-S96.
44. Sugimoto K. Role of STAT3 in inflammatory bowel disease. World J Gastroenterol 2008, 14:5110-5114.
45. Kovarik P., Stoiber D., Eyers P.A., et al. Stress-induced phosphorylation of STAT1 at Ser727 requires p38 mitogen-activated protein kinase whereas IFN-gamma uses a different signaling pathway. Proc Natl Acad Sci USA 1999, 96:13956-13961.
46. Zhang Y., Liu G., Dong Z. MSK1 and JNKs mediate phosphorylation of STAT3 in UVA-irradiated mouse epidermal JB6 cells. J Biol Chem 2001, 276:42534-42542.
47. Zhao K.W., Li D., Zhao Q., et al. Interferon-alpha-induced expression of phospholipid scramblase 1 through STAT1 requires the sequential activation of protein kinase Cdelta and JNK. J Biol Chem 2005, 280:42707-42714.
48. Chung J., Uchida E., Grammer T.C., Blenis J. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol 1997, 17:6508-6516.
49. Lovato P., Brender C., Agnholt J., et al. Constitutive STAT3 activation in intestinal T cells from patients with Crohn's disease. J Biol Chem 2003, 278:16777-16781.
50. Musso A., Dentelli P., Carlino A., et al. Signal transducers and activators of transcription 3 signaling pathway: an essential mediator of inflammatory bowel disease and other forms of intestinal inflammation. Inflamm Bowel Dis 2005, 11:91-98.
51. Mudter J., Weigmann B., Bartsch B., et al. Activation pattern of signal transducers and activators of transcription (STAT) factors in inflammatory bowel diseases. Am J Gastroenterol 2005, 100:64-72.
52. Suzuki A., Hanada T., Mitsuyama K., et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 2001, 193:471-481.
53. Levy D.E., Darnell J.E. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002, 3:651-662.
54. Seidelin J.B., Vainer B., Andresen L., Nielsen O.H. Upregulation of cIAP2 in regenerating colonocytes in ulcerative colitis. Virchows Arch 2007, 451:1031-1038.
55. Seidelin J.B., Nielsen O.H. Attenuated apoptosis response to Fas-ligand in active ulcerative colitis. Inflamm Bowel Dis 2008, 14:1623-1629.
56. Houde M., Laprise P., Jean D., Blais M., Asselin C., Rivard N. Intestinal epithelial cell differentiation involves activation of p38 mitogen-activated protein kinase that regulates the homeobox transcription factor CDX2. J Biol Chem 2001, 276:21885-21894.
57. Rings E.H., Boudreau F., Taylor J.K., Moffett J., Suh E.R., Traber P.G. Phosphorylation of the serine 60 residue within the Cdx2 activation domain mediates its transactivation capacity. Gastroenterology 2001, 121:1437-1450.
58. Boyd M., Hansen M., Jensen T.G., et al. Genome-wide analysis of CDX2 binding in intestinal epithelial cells (Caco-2). J Biol Chem 2010, 285:25115-25125.
59. Coskun M., Troelsen J.T., Nielsen O.H. The role of CDX2 in intestinal homeostasis and inflammation. Biochim Biophys Acta 2011, 1812:283-289.
60. Sipos F., Muzes G., Valcz G., et al. Regeneration associated growth factor receptor and epithelial marker expression in lymphoid aggregates of ulcerative colitis. Scand J Gastroenterol 2010, 45:440-448.
61. Kim S., Domon-Dell C., Wang Q., et al. PTEN and TNF-alpha regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-kappaB-dependent pathway. Gastroenterology 2002, 123:1163-1178.
62. Calon A., Gross I., Lhermitte B., et al. Different effects of the Cdx1 and Cdx2 homeobox genes in a murine model of intestinal inflammation. Gut 2007, 56:1688-1695.
63. Mutoh H., Hayakawa H., Sakamoto H., Sugano K. Homeobox protein CDX2 reduces Cox-2 transcription by inactivating the DNA-binding capacity of nuclear factor-kappaB. J Gastroenterol 2007, 42:719-729.
64. Matthews C.P., Colburn N.H., Young M.R. AP-1 a target for cancer prevention. Curr Cancer Drug Targets 2007, 7:317-324.
65. Binetruy B., Smeal T., Karin M. Ha-Ras augments c-Jun activity and stimulates phosphorylation of its activation domain. Nature 1991, 351:122-127.
66. Shaulian E., Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002, 4:E131-E136.
67. Shaulian E., Karin M. AP-1 in cell proliferation and survival. Oncogene 2001, 20:2390-2400.
68. Olsen J., Kirkeby L.T., Brorsson M.M., et al. Converging signals synergistically activate the LAMC2 promoter and lead to accumulation of the laminin gamma 2 chain in human colon carcinoma cells. Biochem J 2003, 371:211-221.
69. Olsen J., Lefebvre O., Fritsch C., et al. Involvement of activator protein 1 complexes in the epithelium-specific activation of the laminin gamma2-chain gene promoter by hepatocyte growth factor (scatter factor). Biochem J 2000, 347:407-417.
70. Takada Y., Ray N., Ikeda E., et al. Fos proteins suppress dextran sulfate sodium-induced colitis through inhibition of NF-kappaB. J Immunol 2010, 184:1014-1021.
71. Hollenbach E., Neumann M., Vieth M., Roessner A., Malfertheiner P., Naumann M. Inhibition of p38 MAP kinase- and RICK/NF-kappaB-signaling suppresses inflammatory bowel disease. FASEB J 2004, 18:1550-1552.
72. Waetzig G.H., Schreiber S. Review article: mitogen-activated protein kinases in chronic intestinal inflammation - targeting ancient pathways to treat modern diseases. Aliment Pharmacol Ther 2003, 18:17-32.
73. Hommes D., van den B.B., Plasse T., et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002, 122:7-14.
74. Malamut G., Cabane C., Dubuquoy L., et al. No evidence for an involvement of the p38 and JNK mitogen-activated protein in inflammatory bowel diseases. Dig Dis Sci 2006, 51:1443-1453.
75. Otsuka M., Kang Y.J., Ren J., et al. Distinct effects of p38alpha deletion in myeloid lineage and gut epithelia in mouse models of inflammatory bowel disease. Gastroenterology 2010, 138:1255-1265.
76. Kolls J.K., Linden A. Interleukin-17 family members and inflammation. Immunity 2004, 21:467-476.
77. Lee J.C., Laydon J.T., McDonnell P.C., et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372:739-746.
78. Westra J., Doornbos-van der M.B., De B.P., van Leeuwen M.A., van Rijswijk M.H., Limburg P.C. Strong inhibition of TNF-alpha production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor. Arthritis Res Ther 2004, 6:R384-R392.
79. Winzen R., Kracht M., Ritter B., et al. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J 1999, 18:4969-4980.
80. Sandborn W.J., Colombel J.F., Enns R., et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005, 353:1912-1925.
81. Docena G., Rovedatti L., Kruidenier L., et al. Down-regulation of p38 mitogen-activated protein kinase activation and proinflammatory cytokine production by mitogen-activated protein kinase inhibitors in inflammatory bowel disease. Clin Exp Immunol 2010, 162:108-115.
82. Scaldaferri F., Sans M., Vetrano S., et al. The role of MAPK in governing lymphocyte adhesion to and migration across the microvasculature in inflammatory bowel disease. Eur J Immunol 2009, 39:290-300.
83. Fiorucci S., Laufer S.A., Mencarelli A., et al. ML3403, a new p38 MAPK inhibitor, corrects immune dysfunction in rodent models of chronic inflammatory disorders. Gastroenterology 2010, 138(Suppl. 1):S409.
84. Gallo K.A., Johnson G.L. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat Rev Mol Cell Biol 2002, 3:663-672.
85. Ten H.T., van den B.B., Pronk I., Drillenburg P., Peppelenbosch M.P., van Deventer S.J. Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis. Gut 2002, 50:507-512.
86. Karrasch T., Steinbrecher K.A., Allard B., Baldwin A.S., Jobin C. Wound-induced p38MAPK-dependent histone H3 phosphorylation correlates with increased COX-2 expression in enterocytes. J Cell Physiol 2006, 207:809-815.
87. Turner J.R. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 2009, 9:799-809.
88. Egan L.J., de L.A., Lehrman E.D., Myhre G.M., Eckmann L., Kagnoff M.F. Nuclear factor-kappa B activation promotes restitution of wounded intestinal epithelial monolayers. Am J Physiol Cell Physiol 2003, 285:C1028-C1035.
89. Egan L.J., Eckmann L., Greten F.R., et al. IkappaB-kinasebeta-dependent NF-kappaB activation provides radioprotection to the intestinal epithelium. Proc Natl Acad Sci USA 2004, 101:2452-2457.
90. Strauch E.D., Bass B.L., Rao J.N., Vann J.A., Wang J.Y. NF-kappaB regulates intestinal epithelial cell and bile salt-induced migration after injury. Ann Surg 2003, 237:494-501.
91. Dieckgraefe B.K., Weems D.M., Santoro S.A., Alpers D.H. ERK and p38 MAP kinase pathways are mediators of intestinal epithelial wound-induced signal transduction. Biochem Biophys Res Commun 1997, 233:389-394.
92. Lasa M., Abraham S.M., Boucheron C., Saklatvala J., Clark A.R. Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol 2002, 22:7802-7811.
93. Goke M.N., Schneider M., Beil W., Manns M.P. Differential glucocorticoid effects on repair mechanisms and NF-kappaB activity in the intestinal epithelium. Regul Pept 2002, 105:203-214.
94. Modigliani R., Mary J.Y., Simon J.F., et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990, 98:811-818.
95. Jung S., Fehr S., Harder-d'Heureuse J., Wiedenmann B., Dignass A.U. Corticosteroids impair intestinal epithelial wound repair mechanisms in vitro. Scand J Gastroenterol 2001, 36:963-970.
96. Assi K., Pillai R., Gomez-Munoz A., Owen D., Salh B. The specific JNK inhibitor SP600125 targets tumour necrosis factor-alpha production and epithelial cell apoptosis in acute murine colitis. Immunology 2006, 118:112-121.
97. Waetzig G.H., Seegert D., Rosenstiel P., Nikolaus S., Schreiber S. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol 2002, 168:5342-5351.
98. Chromik A.M., Muller A.M., Korner J., et al. Genetic deletion of JNK1 and JNK2 aggravates the DSS-induced colitis in mice. J Invest Surg 2007, 20:23-33.
99. Sandle G.I., Hayslett J.P., Binder H.J. Effect of glucocorticoids on rectal transport in normal subjects and patients with ulcerative colitis. Gut 1986, 27:309-316.
100. Zeissig S., Bergann T., Fromm A., et al. Altered ENaC expression leads to impaired sodium absorption in the noninflamed intestine in Crohn's disease. Gastroenterology 2008, 134:1436-1447.
101. Miampamba M. RDEA119, a potent and highly selective MEK inhibitor ameliorates murine colitis. Gastroenterology 2008, 134(Suppl. 1):107.
102. van den B.B., ten H.T., Van Den Brink G.R., Peppelenbosch M.P., van Deventer S.J. From extracellular to intracellular targets, inhibiting MAP kinases in treatment of Crohn's disease. Ann NY Acad Sci 2002, 973:349-358.
103. van M.C., Peppelenbosch M., te Velde A.A., Van D.S. Inflammatory signal transduction in Crohn's disease and novel therapeutic approaches. Biochem Pharmacol 2002, 64:789-795.
104. Dotan I., Rachmilewitz D., Schreiber S., et al. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease. Gut 2010, 59:760-766.
105. Lowenberg M., Verhaar A., van den B.B., et al. Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's disease. J Immunol 2005, 175:2293-2300.
106. Schreiber S., Feagan B., D'Haens G., et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006, 4:325-334.
107. Gruenbaum L.M., Schwartz R., Woska J.R., et al. Inhibition of pro-inflammatory cytokine production by the dual p38/JNK2 inhibitor BIRB796 correlates with the inhibition of p38 signaling. Biochem Pharmacol 2009, 77:422-432.
108. Iyer S., Lahana R., Buelow R. Rational design and development of RDP58. Curr Pharm Des 2002, 8:2217-2229.
109. Travis S., Yap L.M., Hawkey C., et al. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm Bowel Dis 2005, 11:713-719.
110. Walmsley R.S., Ayres R.C., Pounder R.E., Allan R.N. A simple clinical colitis activity index. Gut 1998, 43:29-32.
111. Wiggin G.R., Soloaga A., Foster J.M., Murray-Tait V., Cohen P., Arthur J.S. MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts. Mol Cell Biol 2002, 22:2871-2881.
112. Jiang Y., Chen C., Li Z., et al. Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J Biol Chem 1996, 271:17920-17926.
113. Yang S.H., Galanis A., Sharrocks A.D. Targeting of p38 mitogen-activated protein kinases to MEF2 transcription factors. Mol Cell Biol 1999, 19:4028-4038.
114. Han J., Jiang Y., Li Z., Kravchenko V.V., Ulevitch R.J. Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature 1997, 386:296-299.
115. Deak M., Clifton A.D., Lucocq L.M., Alessi D.R. Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J 1998, 17:4426-4441.
116. Wang X.Z., Ron D. Stress-induced phosphorylation and activation of the transcription factor CHOP (GADD153) by p38 MAP kinase. Science 1996, 272:1347-1349.
117. Sanchez-Prieto R., Rojas J.M., Taya Y., Gutkind J.S. A role for the p38 mitogen-acitvated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents. Cancer Res 2000, 60:2464-2472.
118. Janknecht R., Hunter T. Convergence of MAP kinase pathways on the ternary complex factor Sap-1a. EMBO J 1997, 16:1620-1627.
119. Whitmarsh A.J., Yang S.H., Su M.S., Sharrocks A.D., Davis R.J. Role of p38 and JNK mitogen-activated protein kinases in the activation of ternary complex factors. Mol Cell Biol 1997, 17:2360-2371.
120. Yang S.H., Whitmarsh A.J., Davis R.J., Sharrocks A.D. Differential targeting of MAP kinases to the ETS-domain transcription factor Elk-1. EMBO J 1998, 17:1740-1749.
121. Engelman J.A., Lisanti M.P., Scherer P.E. Specific inhibitors of p38 mitogen-activated protein kinase block 3T3-L1 adipogenesis. J Biol Chem 1998, 273:32111-32120.
122. Tanos T., Marinissen M.J., Leskow F.C., et al. Phosphorylation of c-Fos by members of the p38 MAPK family. Role in the AP-1 response to UV light. J Biol Chem 2005, 280:18842-18852.
123. Derijard B., Hibi M., Wu I.H., et al. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 1994, 76:1025-1037.
124. Morton S., Davis R.J., McLaren A., Cohen P. A reinvestigation of the multisite phosphorylation of the transcription factor c-Jun. EMBO J 2003, 22:3876-3886.
125. Pulverer B.J., Kyriakis J.M., Avruch J., Nikolakaki E., Woodgett J.R. Phosphorylation of c-jun mediated by MAP kinases. Nature 1991, 353:670-674.
126. Li B., Tournier C., Davis R.J., Flavell R.A. Regulation of IL-4 expression by the transcription factor JunB during T helper cell differentiation. EMBO J 1999, 18:420-432.
127. Yazgan O., Pfarr C.M. Regulation of two JunD isoforms by Jun N-terminal kinases. J Biol Chem 2002, 277:29710-29718.
128. Gupta S., Campbell D., Derijard B., Davis R.J. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 1995, 267:389-393.
129. Livingstone C., Patel G., Jones N. ATF-2 contains a phosphorylation-dependent transcriptional activation domain. EMBO J 1995, 14:1785-1797.
130. Whitmarsh A.J., Shore P., Sharrocks A.D., Davis R.J. Integration of MAP kinase signal transduction pathways at the serum response element. Science 1995, 269:403-407.
131. Alarcon-Vargas D., Ronai Z. c-Jun-NH2 kinase (JNK) contributes to the regulation of c-Myc protein stability. J Biol Chem 2004, 279:5008-5016.
132. Buschmann T., Potapova O., Bar-Shira A., et al. Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol Cell Biol 2001, 21:2743-2754.
133. Fuchs S.Y., Adler V., Pincus M.R., Ronai Z. MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci USA 1998, 95:10541-10546.
134. Chow C.W., Rincon M., Cavanagh J., Dickens M., Davis R.J. Nuclear accumulation of NFAT4 opposed by the JNK signal transduction pathway. Science 1997, 278:1638-1641.
135. Cai Y., Lechner M.S., Nihalani D., Prindle M.J., Holzman L.B., Dressler G.R. Phosphorylation of Pax2 by the c-Jun N-terminal kinase and enhanced Pax2-dependent transcription activation. J Biol Chem 2002, 277:1217-1222.
136. Essers M.A., Weijzen S., de Vries-Smits A.M., et al. FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. EMBO J 2004, 23:4802-4812.
137. Price M.A., Rogers A.E., Treisman R. Comparative analysis of the ternary complex factors Elk-1, SAP-1a and SAP-2 (ERP/NET). EMBO J 1995, 14:2589-2601.
138. Marais R., Wynne J., Treisman R. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell 1993, 73:381-393.
139. Monje P., Marinissen M.J., Gutkind J.S. Phosphorylation of the carboxyl-terminal transactivation domain of c-Fos by extracellular signal-regulated kinase mediates the transcriptional activation of AP-1 and cellular transformation induced by platelet-derived growth factor. Mol Cell Biol 2003, 23:7030-7043.
140. Sears R., Leone G., DeGregori J., Nevins J.R. Ras enhances Myc protein stability. Mol Cell 1999, 3:169-179.
141. Kretzschmar M., Doody J., Massague J. Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. Nature 1997, 389:618-622.
142. Kretzschmar M., Doody J., Timokhina I., Massague J. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev 1999, 13:804-816.
143. Roelen B.A., Cohen O.S., Raychowdhury M.K., et al. Phosphorylation of threonine 276 in Smad4 is involved in transforming growth factor-beta-induced nuclear accumulation. Am J Physiol Cell Physiol 2003, 285:C823-C830.
144. Wang S., Shi X. Mechanisms of Cr(VI)-induced p53 activation: the role of phosphorylation, mdm2 and ERK. Carcinogenesis 2001, 22:757-762.
145. Vorbrueggen G., Lovric J., Moelling K. Functional analysis of phosphorylation at serine 532 of human c-Myb by MAP kinase. Biol Chem 1996, 377:721-730.
146. Milanini-Mongiat J., Pouyssegur J., Pages G. Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription. J Biol Chem 2002, 277:20631-20639.
147. Gupta P., Prywes R. ATF1 phosphorylation by the ERK MAPK pathway is required for epidermal growth factor-induced c-jun expression. J Biol Chem 2002, 277:50550-50556.
148. Liang Q., Wiese R.J., Bueno O.F., Dai Y.S., Markham B.E., Molkentin J.D. The transcription factor GATA4 is activated by extracellular signal-regulated kinase 1- and 2-mediated phosphorylation of serine 105 in cardiomyocytes. Mol Cell Biol 2001, 21:7460-7469.
149. Towatari M., May G.E., Marais R., et al. Regulation of GATA-2 phosphorylation by mitogen-activated protein kinase and interleukin-3. J Biol Chem 1995, 270:4101-4107.
150. Toiyama Y., Mizoguchi A., Kimura K., et al. Persistence of gene expression changes in noninflamed and inflamed colonic mucosa in ulcerative colitis and their presence in colonic carcinoma. World J Gastroenterol 2005, 11:5151-5155.
151. Rosman-Urbach M., Niv Y., Birk Y., et al. A high degree of aneuploidy, loss of p53 gene, and low soluble p53 protein serum levels are detected in ulcerative colitis patients. Dis Colon Rectum 2004, 47:304-313.
152. Schreiber S., Rosenstiel P., Hampe J., et al. Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut 2002, 51:379-385.
153. Macpherson A.J., Chester K.A., Robson L., Bjarnason I., Malcolm A.D., Peters T.J. Increased expression of c-myc proto-oncogene in biopsies of ulcerative colitis and Crohn's colitis. Gut 1992, 33:651-656.
154. Monteleone G., Kumberova A., Croft N.M., McKenzie C., Steer H.W., Macdonald T.T. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001, 108:601-609.
155. Haveri H., Ashorn M., Iltanen S., Wilson D.B., Andersson L.C., Heikinheimo M. Enhanced expression of transcription factor GATA-4 in inflammatory bowel disease and its possible regulation by TGF-beta1. J Clin Immunol 2009, 29:444-453.